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Introduction: Recent progress in immunotherapy has introduced 
programmed death-1 (PD-1)/ programmed death-ligand 1 (PD-L1) blockade 
as a novel target to eradicate tumors, but its use has been mainly confined to 
recurrent or metastatic settings. Radiotherapy (RT), a major part of anti-
cancer treatment, directly kills tumor cells, and subsequent anti-tumor 
immune responses are up-regulated. However, immunologic impacts of RT on 
PD-1/PD-L1 immune checkpoint activity has not been much investigated. 
This study evaluated RT-induced alterations of the PD-1/PD-L1 checkpoint 
molecules based on a murine colon carcinoma and human rectal cancer 
treated with preoperative chemoradiotherapy (CRT). 
ii 
 
Methods: CT26 colon carcinoma cell line was subcutaneously inoculated on 
the right hind leg of BALB/c mice. Based on tumor growth curves after 
irradiation of 15 Gy x 1 fx or 5 Gy x 3 fx, mouse tumors were surgically 
resected on 4 different time points: “Pre-RT”, non-irradiated status just prior 
to initiation of RT; “Early”, the early phase of RT response; “Nadir”, 
representing minimal tumor volume; and “Regrowth”, with regrown tumors 
after RT. Defining the Day 1 as an initiation of RT, tumor tissues were 
obtained on Day 1, 6, 12, and 22, and Day 1, 6, 10, and 20, with single 
ablative and fractionated dose regimen, respectively. PD-L1 expression on 
tumor cells, PD-1 expression on tumor-infiltrating CD4+ and CD8+ T cells, 
and proportions of tumor-infiltrating CD4+ and CD8+ T cell populations were 
estimated using flow cytometry analysis. Considering human data, we 
conducted paired analysis using pre-CRT biopsies and the corresponding 
post-CRT resected tissues of 123 rectal cancer patients undergoing 
preoperative CRT followed by surgery between 2005 and 2012. 
Immunohistochemistry of PD-L1, PD-1, and CD8 was analyzed along with 
other clinicopathologic features and survival outcomes. 
Results: PD-L1 expression on mouse tumor cells surged within a few days 
after completion of RT, followed by abrupt decreases on the “Nadir” and 
“Regrowth” phases (P < .001 and equal to .002 for single ablative and 
fractionated RT, respectively). PD-1-positivity (%) on CD4+ T cells was not 
significantly different according to different time points (P = .656 and .223 
for single ablative and fractionated RT, respectively). On the contrary, PD-1-
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positive proportions (%) in CD8+ T cells sharply increased, and the high-level 
was sustained until the “Regrowth” phase (P < .001 for all paired comparisons 
between “Pre-RT” and others). During RT response of “Early” and “Nadir” 
time points, CD4+ T cells decreased, but CD8+ T cells increased. The 
alterations were reversed at “Regrowth” phase, with increasing and decreasing 
again in CD4+ and CD8+ T cell populations, respectively (P < .001 all paired 
comparisons between “Pre-RT” and others). 
In the immunohistochemistry of rectal cancer, PD-L1 expression levels and 
density of CD8+ tumor-infiltrating lymphocytes (TILs) increased after CRT (P 
< .001 for both). Considering PD-1 expression, its pre-CRT intensity was 
scanty, but markedly increased after CRT. With cutoffs using each median 
value, sustained higher expression of PD-L1 at pre- and post-CRT (high-to-
high) was associated with less increase in the density of CD8+ TILs (P = .020). 
Patients with sustained high-to-high PD-L1 expression had poorer overall 
survival (OS) and disease-free interval (DFI) in univariate Kaplan-Meier 
analysis (P = .018 and .029, respectively), with inferior DFI in low-to-low 
density CD8+ TILs (P = .010). In multivariate analysis, two subgroups with 
high baseline PD-L1 expression level showed worse OS, but the highest risk 
was observed with the high-to-high alteration (hazard ratio [HR] 8.34, 95% 
confidence interval [CI] 1.85–37.53 and HR 11.03, 95% CI 2.33–52.29 for 
high-to-low and high-to-high, respectively). 
Conclusions: This study verified radiation-induced immunologic shift toward 
increases of the PD-1/PD-L1 checkpoint activity and density of CD8+ TILs. 
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However, the change was maximal at the early phase of RT response, which 
highlights the need of concurrent combinatory strategy of PD-L1 blockade 
and RT. The alteration profiles of checkpoint-related molecules identified the 
subset of patients with poor prognosis, suggesting potential candidates who 
can benefit from combining checkpoint inhibitors. 
---------------------------------------------------------------------------------------------- 
Keywords: PD-L1, PD-1, CD8, radiotherapy, mouse tumor model, rectal 
cancer, chemoradiotherapy 
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Cancer immunotherapy has been one of the major anti-cancer modalities to suppress 
or eradicate tumors. In the function of T cell-mediated anti-cancer immunity, 
regulation of co-stimulatory or inhibitory signals is an important underlying 
mechanism (1). Immune checkpoints are molecules that either up-regulate or down-
regulate cascade immune reactions, which has been increasingly considered as a 
novel target for cancer treatment (2). 
Programmed death-1 (PD-1) (known as CD279) is a cell surface receptor 
expressed on T cells and pro-B cells (3). Programmed death-ligand 1 (PD-L1) 
(known as B7-H1 or CD274) is its main ligand widely expressed on antigen-
presenting cells, normal epithelial or endothelial tissues, and tumor cells (3). PD-
1/PD-L1 is one of the prominent immune checkpoints, well-known as inhibitory 
mechanisms of immune responses (4). Their molecular interaction under pro-
inflammatory conditions induces co-inhibitory signal of immune responses with 
down-regulation of cytokine levels and effector T cells (5). Although the PD-1/PD-
L1 immune checkpoint plays a physiologic function in down-regulating harmful 
inflammation reactions, the inhibitory effect leads to immune evasion and further 
tumor progression in the tumor microenvironment (6). The advent of PD-1/PD-L1-
inhibiting strategy has highlighted the critical role of anti-tumor immunity in a 
variety of human cancers. 
Colorectal cancer is the third most common cancer worldwide (7). Despite 
2 
 
technical advances and development of targeted therapies, this malignancy is the 
second to third leading cause of cancer-related deaths (7). Post-treatment failure 
with metastatic tumor spread still needs to be overcome (8). Although the use of the 
PD-1/PD-L1 checkpoint inhibitors has been considered a possible anti-cancer 
treatment option, previous clinical trials could not demonstrate a clear benefit in 
colorectal cancer (9). At baseline for colorectal cancer, PD-L1 expression in tumor 
cells is not often directly linked to their response to the checkpoint blockade therapy, 
whereas the checkpoint inhibitor is more effective in tumors of microsatellite 
instability (MSI) status, rather than microsatellite-stable (MSS) status (10, 11). 
Therefore, determining an optimal indication of the immunotherapeutic approach 
has been of interest to treatment of colorectal cancer. 
With regard to the immunologic equilibrium, it has been known that cytotoxic 
therapies, such as chemotherapy, radiotherapy (RT), and chemoradiotherapy (CRT), 
develop a pro-inflammatory tumor microenvironment, releasing danger signals and 
allowing the activation of tumor-specific adaptive immunity (12, 13). In addition to 
previous investigations demonstrating the effect of RT as an immune adjuvant (14-
17), recent preliminary results have supported combining PD-1/PD-L1 inhibitors 
with chemotherapy or CRT (18-20). To expand the discussion more in clinics, the 
potential for shifting the PD-1/PD-L1 activity through cytotoxic anti-cancer 
treatment needs to be explored. 
In this study, we hypothesized that: 1) PD-1/PD-L1 expressions undergo 
alterations through the time course after RT based on syngeneic murine tumor 
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model; 2) Pre- and post-treatment change of PD-1/PD-L1 status of human cancer 
tissues is in accordance with that of mouse tumors; 3) PD-1/PD-L1 expression 
levels before and/or after treatment are associated with patients’ prognosis. Since 
tumor tissues are not routinely obtained after RT in clinics, CT26 murine colon 
carcinoma model was used for post-RT consecutive monitoring of the checkpoint 
activity. To validate the alteration tendency regarding its prognostic associations in 
human cancer, we performed a paired comparison analysis using 
immunohistochemistry (IHC) of initial biopsies and post-CRT surgical tissues of 
rectal cancer undergoing preoperative CRT followed by surgery. Our results would 
provide knowledge for an optimal schedule and indication of combining strategy of 




MATERIALS AND METHODS 
1. Cell line and animals 
CT26 cell line, a murine colon carcinoma of BALB/c mouse, was purchased from 
American Type Culture Collection. The cells were maintained in Roswell Park 
Memorial Institute medium (Welgene, Gyeongsan-si, Gyeongsangbuk-do, Korea) 
supplemented with 10% fetal bovine serum (Gibco, Grand Island, NY, USA) and 
antibiotic-antimycotic (100x) (Gibco, Grand Island, NY, USA), and grown in an 
incubator with humidified atmosphere of 95% air and 5% CO2 at 37.5 °C. 
Male 6-week old BALB/c mice were used in this study. The animal experiment 
was approved by the Institutional Animal Care and Use Committee of Seoul 
National University Hospital (approval number: 15-0199-C1A0). All experimental 
procedures were conducted under the regulations and standards of the institution. 
 
2. Preliminary experiments 
To determine details of mouse tumor model, such as tumor cell counts, inoculation 
methods, radiation dose, energy, and initial tumor volume at the start of irradiation, 
other prior CT26 murine model-based protocols were considered (17, 21). In the 
pilot study, 2 x 105 CT26 cells were subcutaneously inoculated at right lower hind 
leg of mice. Mouse tumors were irradiated with 6-MV X-ray photon energy once 
daily using a linear accelerator (Varian Medical systems, Palo Alto, CA). A custom-
made acrylic device was used to immobilize the body and leg tumors (Figure 1). 
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Tumor size was measured every other day using a vernier caliper without treatment 
information. Individual tumor volume was calculated with the formula of 1/2 x 
length x width2 (mm3) 
 
 
Figure 1. Immobilization and irradiation of mouse tumors 
 
Regarding that dose regimens used in the two reference studies are converted to 
biologically effective dose (BED) of 7.5−8 Gy10, our pilot study explored single and 
fractionated radiation dose schemes: 7.5 Gy x 1 fx, 2.5 Gy x 3 fx, 15 Gy x 1 fx, and 
5 Gy x 3 fx. Tumor growth curves of control (no radiation) and the above 4 
experimental groups were compared (Figure 2). To evaluate immunologic effects of 
radiation-induced tumor cell killing, 15 Gy x 1 fx and 5 Gy x 3 fx, showing definite 





Figure 2. Preliminary experiments for tumor growth curves after irradiation: (A) 
Control (no RT), (B) 7.5 Gy x 1 fx, (C) 2.5 Gy x 3 fx, (D) 15 Gy x 1 fx, (E) 5 Gy x 
3 fx. Red arrows indicate the start of irradiation. Representative data (mean ± 
standard deviation) (mm3) of 5 mice per each RT dose regimen. 
 
From comprehensive review of the preliminary results, other experimental 
protocols were determined: tumor cell count of 5 x 105, right lower hind leg as the 
subcutaneous injection site with a fixation device, and initial tumor volume at least 
200 mm3. The same researchers (Y.J.L. and S.R.J.) consistently performed the 
tumor inoculation and irradiation to obtain reproducible results. 
 
3. Mouse tumor model 
Based on tumor growth curves with irradiation, four different time points for 
resection of tumor tissues were determined for each of single ablative and 
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fractionated dose regimen: “Pre-RT”, non-irradiated status just prior to initiation of 
RT; “Early”, the early phase of RT response; “Nadir”, representing minimal tumor 
volume; and “Regrowth”, with regrown tumors after RT (Figure 3). Defining the 
day 1 as an initiation of RT with 15 Gy x 1 fx or 5 Gy x 3 fx, the “Early”, “Nadir”, 
and “Regrowth” phases were in accordance with day 6, 12, and 22, or day 6, 10, and 
20, respectively. Every four mice were sacrificed at each time point for tumor 




Figure 3. Four different time points for evaluation of PD-1/PD-L1 immune 
checkpoint activity on mouse tumor tissues. (A) Single ablative dose (15 Gy x 1 fx) 
and (B) fractionated (5 Gy x 3 fx) irradiation: “Pre-RT”, non-irradiated status just 
prior to initiation of RT; “Early”, the early phase of RT response; “Nadir”, 
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representing minimal tumor volume; and “Regrowth”, with regrown tumors after 
RT. 
 
4. Single cell suspension of mouse tumors 
Tumor tissues were cut up into small pieces and minced using scalpels. For 
digestion, 10x triple enzyme stock solution, consisting of 10 mg/ml collagenase IV, 
200 mg/ml DNase I, 1 mg/ml hyaluronidase, and Hank’s Balanced Salt Solution 
(HBSS) (all Sigma-Aldrich, St. Louis, MO, USA), was added. The sample was 
incubated under 37°C for 30 min, and passed through 70 μm nylon mesh cell 
strainer (Corning, Corning, NY, USA). After repeated washing in HBSS, cells were 
resuspended with plating media. 
 
5. Flow cytometry analysis 
Prepared cells were initially blocked with anti-FcR (BD Biosciences, San Jose, CA, 
USA), and then stained with antibodies against CD45, CD3, CD4, CD8, PD-1 
(BioLegend, San Diego, CA, USA), and PD-L1 (BD Biosciences unless otherwise 
stated). Live cells were gated using a fixable viability stain reagent (BD Biosciences, 
San Jose, CA, USA). Phenotypes of tumor cells and lymphocytes were evaluated. 






Figure 4. Gating method for evaluation of PD-1 expression in subsets of 
CD45+CD3+ cells. (A, B) Selection based on size and granularity information, (C) 
gating for viable cells based on vital dye exclusion pattern, and (D) discrimination 





Figure 5. Gating method for evaluation of PD-L1 expression on tumor cells. (A, B) 
Selection based on size and granularity information, (C) gating for viable cells 





6. Patient population 
Rectal cancer patients undergoing preoperative CRT plus total mesorectal excision 
between 2005 and 2012 at our hospital were reviewed, and a total of 123 patients 
were finally analyzed. The eligibility criteria included: 1) both biopsy and 
postsurgical tumor tissues obtained; 2) clinicopathologic information fully available; 
3) initial cM0 stage; 4) preoperative CRT with conventional fractionation; and 5) 
completion of planned course of CRT plus total mesorectal excision. This study was 
approved by the Institutional Review Board (IRB) of our institution (IRB No. 1503-
039-654). The Declaration of Helsinki principles were followed throughout the 
present analysis. 
Clinical and pathologic tumor stages were classified according to the 7th edition 
of the American Joint Committee on Cancer staging system. The pathologic 
regression grade was based on the Dworak system, from 0 of no regression to 4 of 
complete pathological regression (22). The MSI analysis was performed using 
fluorescent multiplex polymerase chain reaction with the five markers 
recommended by the National Cancer Institute workshop: BAT-25, BAT-26, 
D5S346, D17S250, and D2S123. Using DNA analysis, samples with two or more of 
the markers were considered as MSI-high (MSI-H). The presence of one marker 
corresponded to MSI-low (MSI-L), and the MSS status was diagnosed when all of 
the markers represented stability. 
 
7. Treatment of patients 
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Patients with rectal adenocarcinoma of clinically T3–4 and/or node-positive status 
were referred for preoperative CRT. With a daily fraction size of 1.8 Gy, the median 
total radiation dose was 50.4 Gy (range, 50.4–55.8). The concurrent chemotherapy 
regimen included intravenous 5-fluorouracil (500 mg/m2 for 3 days during the first 
and fifth week of radiation) and oral capecitabine (1,650 mg/m2 daily during the 
course of radiation). Following the preoperative CRT, the patients underwent total 
mesorectal excision, with the median time interval of 52 days (range, 38–82). Most 
patients (92%) received postoperative maintenance chemotherapy. 
 
8. Immunohistochemistry 
Tissue specimens from initial biopsies (pre-CRT) and total mesorectal excision 
(post-CRT) were retrieved from the pathology archive of our institution. The cases 
were reviewed and histologically confirmed as adenocarcinoma. A tissue 
microarray was made with 4-mm cores from formalin-fixed paraffin-embedded 
tissue blocks, with two representative cores of invasive front of tumors for each 
case. For the immunohistochemical staining of PD-L1, PD-1, and CD8, rabbit anti-
PD-L1 antibody Q9NZQ7 (Abcam, Cambridge, MA, USA; 1:700), mouse anti-PD-
1 antibody NAT105 (Cell Marque, Rocklin, CA, USA; 1:100), and rabbit anti-CD8 
antibody SP57 (Roche, Indianapolis, IN, USA; ready-to-use) were used. For the 
immunohistochemical staining, Ventana BenchMark XT autostainer (Ventana 
Medical Systems, Tucson, AZ, USA) was used. Human placenta and tonsil tissues 
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were used for positive control of anti-PD-L1, and PD-1 or CD8 staining, 
respectively (Figure 6). 
 
 
Figure 6. Positive control of immunohistochemistry. Slide views of human (A) 
tonsil and (B) placenta tissues stained with anti-PD-1 and PD-L1 antibody, 
respectively (x200). 
 
9. Pathologic evaluation 
PD-L1 expression in tumor tissues was assessed semi-quantitatively on a 0–3 scale 
(0, no; 1, weak; 2, moderate; and 3, strong expression). H-score was calculated 
using the formula, the representative staining intensity of each case × the percentage 
of expressed tumor cells. Although the PD-L1 molecule is expressed on both tumor 
and tumor-infiltrating immune cells, such as macrophages and lymphocytes, the 
expression on lymphocytes was not sufficiently observed in our paraffin-embedded 
tissues. Then, we designed our study focusing on the altered PD-L1 expression 
based on membranous staining of tumor cells. 
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The CD8-stained slides were scanned using an AperioScanScope (Aperio 
Technologies, Vista, CA, USA). Based on the Aperio nuclear IHC algorithms of 
spectral differentiation between brown (positive) and blue (counter) staining, total 
positivity percentage was scored as 1+ through 3+ for each case. The density of 
CD8+ tumor-infiltrating lymphocytes (TILs) was automatically enumerated, which 
was defined as the total number of 1+ to 3+ cells divided by the total area (mm2). 
Two pathologists (J.K. and S.K.) reviewed the staining results without any clinical 
information of each patient. 
 
10. Statistical analysis 
Tumor growth curve data of CT26 mouse tumor model were presented as mean ± 
standard deviation (SD) of absolute tumor volume (mm3). To evaluate differential 
expression of immunologic markers among the four kinds of time points, one-way 
analysis of variance method was used. The relationships between baseline 
characteristics of rectal cancer patients and PD-L1 expression on tumor cells were 
evaluated by the Pearson’s chi-square or Fisher’s exact test, and the Wilcoxon 
signed-rank test was used for the analysis of CD8+ TILs. In survival analysis, the 
primary outcome of interest was overall survival (OS), which was defined as the 
time period between the start date of CRT and overall death events. Disease-free 
interval (DFI), locoregional relapse-free interval (LRFI), and distant metastasis-free 
interval (DMFI) were estimated based on the overall, locoregional, and distant 
metastatic recurrence events, respectively. Kaplan-Meier analysis with a log-rank 
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test and a Cox proportional hazards model were used to evaluate prognostic factors. 
Statistically significant factors indicating P-values less than 0.05 were considered 






Tumor growth curve after irradiation 
Figure 7 represents the change of absolute tumor volume before and after irradiation 
using the CT26 murine tumor model. When tumors were irradiated with a single 
ablative dose of 15 Gy x 1 fx, the tumor growth delay comprising of descending and 
regrowth change was observed. The consecutive phase of RT response with 5 Gy x 
3 fx was also characteristic, but tumor regrowth appeared earlier than with single 
ablative dose regimen. 
 
 
Figure 7. Change of CT26 tumor volume with irradiation. Black dot symbols and 
error bars indicate mean and SD values from 5 mice per each dose regimen, 
respectively, with (A) single ablative (15 Gy x 1 fx) and (B) fractionated (5 Gy x 3 
fx) RT. Red arrows indicate the time points of tumor resection. Experiments were 




PD-L1 expressions on tumor cells 
Compared to baseline status, irradiated tumors at “Early” phase showed a sharp 
increase of PD-L1 expression on tumor cells. The mean ± SD values of median 
fluorescence intensity (MFI) at “Pre-RT” and “Early” were 1188.8 ± 549.2 and 
4923.0 ± 633.6, and 969.5 ± 187.2 and 4604.8 ± 2021.8 with single ablative and 
fractionated RT, respectively. However, the intensity abruptly decreased again 
through the “Nadir” and “Regrowth” time points, with 1525.5 ± 211.4 and 845.5 ± 
253.9, and 1859.0 ±326.4 and 1584.0 ± 282.1, respectively. All paired comparisons 
between the maximum at “Early” phase and the other time points were statistically 
significant (Figure 8). Representative histograms are presented in Figure 9. 
 
 
Figure 8. Alterations in median fluorescence intensity of PD-L1 on tumor cells 
before and after RT. *P < .05, **P < .01, and ***P < .001 in comparison with the 
“Early” status. Mean ± SD values are represented from 4 mice per each time point 
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after 15 Gy x 1 fx and 5 Gy x 3 fx, respectively. Experiments were repeated twice, 
and the representative data are shown here. 
 
 
Figure 9. PD-L1 expression on tumor cells according to different time points before 
and after RT. Representative results of isotype control (grey shadow) and PD-L1 
(black solid line) with (A−D) single ablative and (E−H) fractionated RT are 
presented, respectively. 
 
PD-1 expression on CD4+ and CD8+ T cells 
Figure 10 represents comparisons of PD-1 expression on CD4+ and CD8+ T cells at 
the different time points. The mean ± SD values of PD-1+ proportions (%) relative 
to CD4+ T cell population at “Pre-RT”, “Early”, “Nadir”, and “Regrowth” phase 
were 57.4 ± 12.6, 63.7 ± 6.4, 57.1 ± 7.5, and 60.0 ± 4.3, and 55.1 ± 15.3, 67.4 ± 
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11.9, 70.6 ± 9.5, and 57.2 ± 8.7 with single ablative and fractionated RT dose, 
respectively (P = .656 and .223, respectively). Considering the expression level of 
PD-1 on CD8+ T cells, the proportions of positive cells increased much sharply, and 
the high-level was sustained until the “Regrowth” phase. The mean ± SD values of 
PD-1-positivity (%) among the CD8+ T cells at the aforementioned 4 time points 
were 23.4 ± 8.9, 95.5 ± 0.7, 93.8 ± 6.2, and 88.0 ± 10.0, and 35.8 ± 7.2, 96.4 ± 2.8, 
96.8 ± 2.0, and 88.3 ± 6.2, with single ablative and fractionated RT dose, 
respectively (P < .001 for both). Figure 11 shows representative histogram data of 
PD-1 expression on CD4+ and CD8+ T cells. 
 
 
Figure 10. PD-1 expression on (A, C) CD4+ and (B, D) CD8+ T cells with single 
ablative (upper panel) and fractionated RT (lower panel). Proportions of PD-1-
positive cells relative to CD4+ and CD8+ subsets are represented as mean (red 
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dotted line) ± SD (error bars of black solid line) values from 4 mice per each time 
point after 15 Gy x 1 fx and 5 Gy x 3 fx, respectively. Experiments were repeated 
twice, and the representative data are shown here. 
 
 
Figure 11. Representative histograms of PD-1 expression on (A−D) CD4+ and 
(E−H) CD8+ T cells according to different time points after RT. Results of isotype 
control (grey shadow) and PD-1 (solid line) are presented. 
 
Proportions of CD4+ and CD8+ T cell subsets 
CD4+ subset decreased after RT, and then increased again at “Regrowth” phase. The 
CD4+ proportions (%) among the T cells at “Pre-RT”, “Early”, “Nadir”, and 
“Regrowth” were 76.7 ± 2.5, 18.0 ± 6.0, 21.7 ± 11.5, and 42.4 ± 5.5, and 89.3 ± 6.9, 
27.2 ± 17.6, 20.4 ± 6.7, and 39.3 ± 7.9 with single ablative and fractionated RT, 
respectively (mean ± SD values) (P < .001 for all paired comparisons between the 
21 
 
“Pre-RT” and others) (Figure 12). On the contrary, the CD8+ T cell population 
sharply increased after RT, and subsequently decreased at “Regrowth” phase. The 
mean ± SD values of CD8-positivity (%) relative to T cell population at the 
aforementioned 4 time points were 8.3 ± 2.5, 66.1 ± 7.6, 67.5 ± 10.8, and 47.2 ± 5.8, 
and 8.8 ± 4.4, 71.9 ± 17.0, 75.6 ± 9.1, and 53.1 ± 15.9 with single ablative and 
fractionated RT, respectively (P < .001 for all paired comparisons between the “Pre-
RT” and others). Figure 13 shows representative contour dot plots of CD4+ and 
CD8+ T cell populations according to different time points. 
 
 
Figure 12. Altered proportions of CD4+ and CD8+ T cell subsets relative to 
CD45+CD3+ cells after irradiation. (A) Single ablative and (B) fractionated dose 
regimen. Mean ± SD values are represented from 4 mice per each time point after 
15 Gy x 1 fx and 5 Gy x 3 fx, respectively. ***P < .001 in comparison with the “Pre-






Figure 13. Change of CD4+ (left panel) and CD8+ (right panel) T cell populations 
according to different time points: (A, B) “Pre-RT”, (C, D) “Early”, (E, F) “Nadir”, 




Clinicopathologic characteristics of rectal cancer patients 
Baseline patient and tumor-related characteristics are summarized in Table 1. The 
median age was 62 years (range, 29–86), and 86 (70%) patients were men. Most 
patients (86%) had cT3 tumors, and 18 (15%), 41 (33%), and 64 (52%) patients 
were diagnosed as pT1, pT2, and pT3 in surgical specimens, respectively. Clinically 
node-positive disease was diagnosed in 106 (86%) patients, and 31 (25%) patients 
had pathologically positive nodal status. Pathologic down-staging of T and N was 
observed in 63 (51%) and 81 (66%) patients, respectively. Based on the Dworak’s 
system (21), pathologic tumor regression of grade 2 or higher was reported in 62 
(51%) patients. The MSI-L or MSI-H status was observed in 9 (7%) patients. 
Concurrent 5-fluorouracil and capecitabine were administered to 90 (73%) and 33 




Table 1. Characteristics of rectal cancer patients 
Variables No. of patients (%) 
Age (years)  
Median (range) 62 (29–86) 
< 62 60 (49) 
≥ 62 63 (51) 
Sex  
  Male 86 (70) 
  Female 37 (30) 
Tumor location from anal verge*  
< 6cm 71 (58) 
≥ 6cm 52 (42) 
Tumor grade (biopsy)  
  Well differentiated 18 (15) 
  Moderately/Poorly differentiated 105 (85) 
cT stage  
  T2 7 (6) 
  T3 106 (86) 
  T4 10 (8) 
cN stage  
  N0 17 (14) 
  N1 91 (74) 
  N2 15 (12) 
Tumor grade (resected)  
  Well differentiated 9 (7) 
  Moderately/Poorly differentiated 114 (93) 
pT stage  
  T1 18 (15) 
  T2 41 (33) 
  T3 64 (52) 
pN stage  
  N0 92 (75) 
  N1 26 (21) 
  N2 5 (4) 
Downstage of T  
  Yes 63 (51) 
  No 60 (49) 
Downstage of N  
  Yes 81 (66) 
  No 25 (20) 
  cN0 17 (14) 
Dworak regression grade  
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  0 5 (4) 
  1 53 (43) 
  2 49 (40) 
  3 13 (11) 
  Not reported 3 (2) 
Lymphatic invasion  
  No 103 (84) 
  Yes 18 (14) 
  Unknown 2 (2) 
Vascular invasion  
  No 116 (94) 
Yes 5 (4) 
Unknown 2 (2) 
Perineural invasion  
No 107 (87) 
Yes 14 (11) 
Unknown 2 (2) 
Microsatellite instability (MSI)  
Microsatellite-stable 91 (74) 
  MSI-low 4 (3) 
  MSI-high 5 (4) 
  Unknown 23 (19) 
Concurrent chemotherapy regimen  
  5-Fluorouracil 90 (73) 
Capecitabine 33 (27) 
Maintenance chemotherapy  
  Yes 113 (92) 
  No 10 (8) 




Change of PD-L1, CD8+ and PD-1+ TILs before and after CRT 
The median H-score at pre- and post-CRT was 0 (range, 0–70) and 100 (range, 0–
270), respectively, and the median density of pre- and post-CRT CD8+ TILs was 
319.66 (range, 20.76–978.08) and 787.05 cells/mm2 (range, 101.39–2100.85), 
respectively. PD-1 staining intensity at initial biopsy was scanty, but increased in 
post-CRT surgical tissues with the median density value of 2.61 cells/mm2 (range, 
0–27.53) (Figure 14). 
 
 
Figure 14. Immunohistochemistry of PD-1 expression at (A, B) pre- and (C, D) 
post-CRT status (x200 for A and C, and x400 for B and D, respectively). 
 
Each of the median values was used as a cutoff stratifying high or low expression 
level before and after CRT. Figure 15 shows the representative IHC slide views of 
PD-L1 and CD8. The scatter dot and before-and-after correspondence plots indicate 
increased PD-L1 expression after CRT (P < .001), and the density of CD8+ TILs 
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was also significantly increased (P < .001) (Figure 16). Figure 17 shows the two 
representative cases with post-CRT increases of the PD-L1 expression and density 
of CD8+ TILs. The post-CRT change in the level of CD8+ TILs for each patient was 
calculated from the formula, ΔCD8+ TILs = density of post-CRT - pre-CRT CD8+ 
TILs. Patients with a sustained high PD-L1 level both with pre- and post-CRT 
status (high-to-high) showed significantly lower ΔCD8+ TILs than the others (P 
= .020) (Figure 18). 
 
 
Figure 15. Representative slide views of pre-CRT (A) low and (B) high and post-
CRT (C) low and (D) high PD-L1 expressions (upper panel) (x200). Pre-CRT (E) 






Figure 16. Increased PD-L1 expression and density of CD8+ TILs after CRT. 
Scatter dot and correspondence plots of (A, C) PD-L1 H-score and (B, D) CD8+ 





Figure 17. Representative slide views of two cases with CRT-induced increases in 
the levels of (A, B) PD-L1 and (C, D) CD8+ TILs, respectively (x200). 
 
 
Figure 18. Pre- and post-CRT difference of the density of CD8+ TILs according to 
the alteration of PD-L1 expression level, high-to-high vs. others. Red dotted lines 




Table 2 and 3 represent the association between clinicopathologic characteristics 
and the expression level of PD-L1 and CD8+ TILs, respectively. Tumor location ≥ 
6cm from the anal verge was associated with higher pre-CRT PD-L1 expression and 
post-CRT CD8+ TILs density (P = .035 for both). Women showed significantly 





Table 2. Associations between patient characteristics and the expression level of PD-L1 before and after CRT 
Variables N 
Pre-CRT [N (%)] 
P 









Age (years)        
<62 60 46 (52) 14 (40) .219 32 (48) 28 (49) .944 
  ≥62 63 42 (48) 21 (60)  34 (52) 29 (51)  
Sex        
  Male 86 62 (70) 24 (69) .837 47 (71) 39 (68) .736 
  Female 37 26 (30) 11 (31)  19 (29) 18 (32)  
Tumor location*        
< 6cm 71 56 (64) 15 (43) .035 43 (65) 28 (49) .073 
≥ 6cm 52 32 (36) 20 (57)  23 (35) 29 (51)  
Tumor grade (biopsy)        
  Well differentiated 18 13 (15) 5 (14) .945 11 (17) 7 (12) .493 
Moderately/Poorly differentiated 105 75 (85) 30 (86)  55 (83) 50 (88)  
cT stage        
  T2-3 113 81 (92) 32 (91) .910 62 (94) 51 (89) .511 
  T4 10 7 (8) 3 (9)  4 (6) 6 (11)  
cN stage        
  N0 17 15 (17) 2 (6) .148 10 (15) 7 (12) .645 
  N1-2 106 73 (83) 33 (94)  56 (85) 50 (88)  
Tumor grade (surgical)        
  Well differentiated 9 8 (9) 1 (3) .443 6 (9) 3 (5) .502 
Moderately/Poorly differentiated 114 80 (91) 34 (97)  60 (91) 54 (95)  
pT stage        
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  T1 18 11 (13) 7 (20) .394 11 (17) 7 (12) .776 
  T2 41 32 (36) 9 (26)  21 (32) 20 (35)  
  T3 64 45 (51) 19 (54)  34 (51) 30 (53)  
pN stage        
  N0 92 67 (76) 25 (71) .587 54 (82) 38 (67) .054 
  N1-2 31 21 (24) 10 (29)  12 (18) 19 (33)  
Downstage of T        
  Yes 63 46 (52) 17 (49) .711 35 (53) 28 (49) .666 
  No 60 42 (48) 18 (51)  31 (47) 29 (51)  
Downstage of N§        
  Yes 81 56 (77) 25 (76) .915 47 (84) 34 (68) .054 
  No 25 17 (23) 8 (24)  9 (16) 16 (32)  
Dworak regression grade        
  0-1 58 43 (50) 15 (44) .561 26 (41) 32 (57) .071 
  ≥ 2 62 43 (50) 19 (56)  38 (59) 24 (43)  
Lymphatic invasion        
  No 103 72 (84) 31 (89) .584 56 (86) 47 (84) .732 
  Yes 18 14 (16) 4 (11)  9 (14) 9 (16)  
Vascular invasion        
  No 116 83 (96) 33 (94) .626 64 (98) 52 (93) .181 
  Yes 5 3 (4) 2 (6)  1 (2) 4 (7)  
Perineural invasion        
  No 107 76 (88) 31 (89) .975 60 (92) 47 (84) .151 
  Yes 14 10 (12) 4 (11)  5 (8) 9 (16)  
Microsatellite instability        
No 91 67 (92) 24 (89) .699 44 (90) 47 (92) .738 
Yes 9 6 (8) 3 (11)  5 (10) 4 (8)  
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*Distance from anal verge. 













Age (years)      
<62 60 319.66 .752 783.47 .816 
  ≥62 63 320.61 787.05 
Gender      
  Men 86 314.87 .133 721.15 .013 
  Women 37 352.27 935.34 
Tumor location*      
< 6cm 71 321.29 .302 729.60 .035 
≥ 6cm 52 313.67 862.04 
Tumor grade (biopsy)      
  Well differentiated 18 416.98 .060 625.96 .052 
Moderately/Poorly differentiated 105 308.76 844.10 
cT stage      
  T2 7 318.31 .291 902.79 .202 
  T3 106 324.79 765.01 
  T4 10 272.53 1222.75 
cN stage      
  N0 17 318.31 .512 749.02 .224 
  N1-2 106 320.48 795.94 
Tumor grade (surgical)      
  Well differentiated 9 416.98 .836 625.96 .641 
Moderately/Poorly differentiated 114 308.76 844.10 
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pT stage      
  T1 18 357.83 .187 659.74 .316 
  T2 41 326.66 888.33 
  T3 64 301.15 749.96 
pN stage      
  N0 92 322.92 .283 800.56 .284 
  N1-2 31 304.13 606.32 
Downstage of T      
  Yes 63 332.50 .165 854.84 .175 
  No 60 299.45 732.75 
Downstage of N§      
  Yes 81 327.14 .400 844.10 .146 
  No 25 304.13 586.42 
Dworak regression grade      
  0-1 58 302.56 .331 780.41 .625 
  ≥ 2 62 327.63 797.79 
Lymphatic invasion      
  No 103 328.48 .004 793.17 .382 
  Yes 18 225.65 551.47 
Vascular invasion      
  No 116 320.48 .260 780.41 .649 
  Yes 5 176.99 915.67 
Perineural invasion      
  No 107 329.33 .027 793.17 .296 
  Yes 14 250.83 585.22 
Microsatellite instability      
  No 91 319.66 .559 798.71 .061 
36 
 
  Yes 9 380.80  935.34  
*Distance from anal verge. 




The five-year rates of OS and DFI were 83.4% and 79.2%, respectively, with a 
median follow-up time of 57.4 months (range, 6.2–134.7). By defining a low or 
high expression level for PD-L1, as well as the density of CD8+ TILs based on the 
median values, subgroups with low-to-low, low-to-high, high-to-low, and high-to-
high alterations before and after CRT could be specified for each of the markers (n 
= 44, 44, 22, and 13 for PD-L1; n = 33, 29, 29, and 32 for CD8+ TILs, respectively). 
The high-to-high PD-L1 group exhibited poorer OS, DFI, and DMFI (P = .018, .029, 
and .023, respectively) (Figure 19), and patients with a low-to-low CD8+ TIL 
density had an inferior DFI, LRFI, and DMFI (P = .010, .014, and .025, respectively) 
(Figure 20). Considering post-CRT density of PD-1+ TILs, there were no 
differences in OS, DFI, LRFI, and DMFI between low vs. high expression level (P 





Figure 19. Kaplan-Meier curves according to pre- and post-CRT PD-L1 alteration 
patterns. (A) Overall survival, (B) disease-free interval, (C) locoregional relapse-





Figure 20. Kaplan-Meier curves according to the CRT-induced alteration of the 
density of CD8+ TILs. (A) Overall survival, (B) disease-free interval, (C) 
locoregional relapse-free interval, and (D) distant metastasis-free interval. 
 
Under the assumption that high-to-high PD-L1 expression and low-to-low density 
of CD8+ TILs are immunologic risk factors, the study population was classified into 
two groups: one consisting of subjects with neither risk factor and the other 
consisting of subjects with at least one risk factor. Patients devoid of risk factors 
had superior OS, DFI, LRFI, and DMFI (P = .020, .002, .017, and .004, respectively) 
(Figure 21). Subgroup analysis for patients with high-to-high PD-L1 expression 
revealed differences in the 5-year rates of OS, DFI, LRFI, and DMFI with respect to 
the relative density of post-CRT CD8+ TILs (low vs. high), as follows: 47.6% vs. 
83.3%, 28.6% vs. 83.3%, 71.4% vs. 100%, and 28.6% vs. 83.3%, respectively. 
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However, none of them was statistically significant, due to limited sample size 
within each subgroup. 
 
 
Figure 21. Kaplan-Meier curves according to the existence or non-existence of each 
of the risk factors: high-to-high PD-L1 level and low-to-low density of CD8+ TILs. 
(A) Overall survival, (B) disease-free interval, (C) locoregional relapse-free interval, 
and (D) distant metastasis-free interval. 
 
Table 4 shows the results of multivariate analysis. In OS, two subgroups with 
high baseline PD-L1 expression level, the high-to-low and high-to-high alterations, 
showed poor prognosis (hazard ratio [HR] 8.34, 95% confidence interval [CI] 1.85–
37.53 and HR 11.03, 95% CI 2.33–52.29, respectively). Due to a relationship 
41 
 
between PD-L1 expression and the density of CD8+ TILs alterations (23), two Cox 
regression models were utilized to assess prognostic factors of DFI. There was a 
marginally significant association indicating inferior outcome of tumor recurrence 





Table 4. Multivariate analysis for overall survival and disease-free interval according to pre- and post-CRT alterations of PD-L1 
and CD8+ TILs 
Variables* 
Overall survival Disease-free interval (I) Disease-free interval (II) 
HR 95% CI P HR 95% CI P HR 95% CI P 
Sex          
  Male 1         
  Female 0.46 0.12–1.80 .265       
Tumor location†          
≥ 6cm 1         
< 6cm 3.85 1.24–11.99 .020       
pT stage          
  T1-2 1   1   1   
  T3 0.31 0.08–1.26 .102 0.71 0.19–2.61 .606 0.74 0.19–2.88 .669 
pN stage          
  N0 1   1   1   
  N1-2 2.42 0.82–7.17 .111 1.36 0.52–3.58 .529 1.13 0.43–3.01 .803 
Downstaging          
  Yes 1   1   1   
  No 6.92 0.96–49.91 .055 4.75 1.09–20.61 .037 3.57 0.73–17.32 .115 
Dworak regression grade          
  0-1 1   1   1   
  2-3 0.44 0.16–1.18 .102 0.53 0.19–1.46 .217 0.34 0.12–0.91 .033 
Lymphatic invasion          
  No 1   1   1   
  Yes 4.46 1.58–12.60 .005 4.16 1.67–10.34 .002 3.04 1.23–7.48 .016 
Vascular invasion          
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  No    1   1   
  Yes    3.90 0.94–16.14 .061 5.69 1.24–26.11 .025 
Perineural invasion          
  No 1   1   1   
  Yes 1.39 0.42–4.60 .595 1.63 0.61–4.39 .330 2.06 0.80–5.28 .134 
PD-L1 (pre and post)§          
Low-to-low 1   1      
Low-to-high 1.21 0.26–5.56 .807 1.23 0.41–3.74 .714    
High-to-low 8.34 1.85–37.53 .006 1.15 2.82–4.71 .844    
High-to-high 11.03 2.33–52.29 .002 3.81 0.96–15.12 .057    
CD8+ TILs (pre and post)§          
High-to-high       1   
High-to-low       1.18 0.31–4.46 .812 
Low-to-high       0.31 0.06–1.70 .177 
Low-to-low       1.53 0.51–4.55 .447 
*Clinico-pathological variables with P-values <0.05 in univariate analysis were included. 
†Distance from anal verge. 






This study explored the RT-induced alterations of PD-1/PD-L1 immune checkpoint 
based on the CT26 murine tumor model and human rectal cancer tissues. When 
mouse tumors were irradiated with single ablative and fractionated dose regimen, 
PD-L1 expression on CT26 tumor cells was highest at the post-RT early phase of 
descending tumor volume, but abruptly decreased through the “Nadir” and 
“Regrowth” phases. With a significant increase of CD8+ T cell population, PD-1 
expression level on CD8+ T cells was significantly elevated after RT, but not on 
CD4+ T cells. In rectal cancer patients treated with preoperative CRT, the 
expression level of PD-1/PD-L1 checkpoint and the density of CD8+ TILs markedly 
increased after the treatment. Classifying the patient population according to 
alteration profiles of PD-L1 or CD8+ TIL levels, either a high-to-high H-score of 
PD-L1 or low-to-low density of CD8+ TILs was associated with worse survival 
outcomes than those of other groups. Multivariate analysis showed a significant 
association between high baseline PD-L1 expression and poor OS, with the highest 
risk observed in the high-to-high PD-L1 subgroup. 
From our results of murine tumor model and rectal cancer analysis, more 
prominent tumor-specific immune responses after RT could be expected. Irradiation 
of tumor tissues up-regulates tumor-associated antigens and death receptors, such as 
Fas cell surface death receptor, major histocompatibility complex molecules, and 
other adhesion-related molecules, and this is an important underlying mechanism of 
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immunogenic tumor cell death (24). In particular, a surge of tumor antigen loading 
increases inflammatory cytokines and effector T cells, thereby shifting the 
immunologic equilibrium of the tumor microenvironment (25, 26). However, the 
immune system functions with a dynamic balance between stimulatory and 
inhibitory forces, so this up-shift in anti-tumor immunity is a well-known trigger for 
inhibitory immune checkpoints (1). The simultaneous up-regulation of immune 
checkpoint activity and cytotoxic CD8+ T cells in both murine and human models is 
suggestive of this aspect. 
There have been several preclinical studies to investigate how RT affects PD-
1/PD-L1 activity in tumors. In an initial research by Deng et al (16), the expression 
level of PD-1/PD-L1 checkpoint molecules was evaluated using TUBO cell line. 
Three days after 12 Gy-single dose RT, PD-L1 expression on tumor cells increased, 
whereas PD-1 expression level was not significantly different compared to non-
irradiated tumors. The radiation-induced effect on PD-1/PD-L1 molecules has also 
been explored using CT26 tumor, but the effect was not monitored through the time 
course after irradiation (17). 
In this study, more prolonged tumor growth delay after 15 Gy x 1 fx than 5 Gy x 
3 fx is related to differential level of BED. Nevertheless, either single ablative or 
fractionated RT up-regulated the PD-L1 expression on tumor cells and PD-1 on 
CD8+ T cells. A landmark preclinical study using murine melanoma cells also stated 
that single dose RT of 20 Gy x 1 fx dramatically increased T-cell priming in a CD8+ 
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T cell-dependent fashion (27). However, tumors irradiated with 5 Gy x 4 fx rapidly 
relapsed, which was analogous to another mouse model of CD8-depleted 20 Gy x 1 
fx. The most important factors for these contradictory results might be differences 
in intrinsic biologic character of tumor cells and radiation-induced tumor cell-
killing effect. The B16 melanoma cell line is characterized to be immunogenic and 
relatively resistant to irradiation (28). Additionally, the fractionated RT regimen of 
5 Gy x 4 fx was delivered over 2 weeks, not for 4 consecutive days, suggesting 
higher potential of damage repair process. In a recent study by Sato et al, depletion 
of BRCA2 or Ku80 up-regulated PD-L1 expression, highlighting the regulatory role 
of double-strand break repair in the immunologic tumor microenvironment (29). 
Therefore, the aforementioned results indicating little immunologic impact of 
fractionated irradiation need to be interpreted with caution. 
However, the RT-induced immediate increase and subsequent decrease of PD-L1 
expression within a few days were remarkable, whereas the high-level PD-1-
positivity on CD8+ T cells was maintained over the “Nadir” and “Regrowth” phase. 
This discordance in altered profile of PD-1 and PD-L1 might be because of 
differential induction of expression as a receptor and ligand, respectively, and this 
aspect suggests that the receptor-ligand binding activity and related cascade 
responses would be higher during the early response of RT than a later time. Thus, 
our results highlight the need of concurrent combination of RT and PD-1/PD-L1 
blockade to obtain therapeutic effect to a larger extent. 
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Several previous syngeneic mouse tumor models have been used to evaluate 
synergistic effect of combinatory treatment of PD-L1 blockade and irradiation. 
When CT26 tumors were treated with anti-PD-L1 inhibitor and RT (2 Gy x 5 fx) 
together (17), the degree of anti-cancer effect was greater and more long-lasting. 
Three different combinatory schedules were compared, and combining PD-L1 
blockade at the first day of RT concurrently resulted in greater tumor-cell killing. 
Our study of tracking PD-1/PD-L1 activity through the post-RT time course 
supports the superiority of concurrent initiation of the combinatory treatment, rather 
than other sequential methods. 
Nevertheless, the results from animals cannot be directly extrapolated to clinics. 
Most of the immunocompetent tumor models were based on subcutaneous tumor 
tissues. Subcutaneous tumors represent a relatively hypoxic tumor 
microenvironment compared to that of orthotopic organ sites (30). Considering the 
potential relationship between oxygen concentration and PD-1/PD-L1 activity, more 
elevated PD-L1 expression level under hypoxic status has been demonstrated (31). 
Although preclinical data from mouse models are needed for developing 
immunotherapy, whether the murine immune system can explain the tumor 
microenvironment of human cancers is not clear (32). From this study consisting of 
both murine colon carcinoma model and human rectal cancer tissues, we could 
obtain comprehensive data of the RT-induced effects on PD-1/PD-L1 axis. 
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Until recently, there have been a few IHC-based investigations to evaluate the 
impact of cytotoxic anti-cancer treatments on PD-L1 expression and CD8+ TIL 
levels (33-37). Similar to our results, a recent study reported up-regulated PD-L1 
expression after CRT for rectal cancer (33). However, pre- and post-CRT IHC 
results were matched and compared only in a small number of patients (n = 63), and 
there was no further information on TILs in the tumor microenvironment. There 
was a paired analysis of CD8+ TILs (n = 93), but PD-L1 expression levels were not 
evaluated (34). Other studies did not assess the potential prognostic significance of 
CRT-induced alterations in immunologic biomarkers (35-37). Ironically, some 
previous studies reported a statistically significant and better prognosis in patients 
with higher PD-L1 expression (33, 38). These contradictory results might be due to 
inherent confounding factors, such as various kinds of antibodies, inconsistent 
cutoff values, assay conditions, tumor heterogeneity, and dynamic immune 
responses. Nevertheless, the prognostic impact of checkpoint molecules has been 
announced, which suggests that immune checkpoints are clinically relevant in 
human cancers. Since this study is the largest paired IHC analysis of PD-L1 
expression and density of CD8+ TILs to date, it is able to offer useful clinical and 
prognostic information. 
Approximately 15% of colorectal cancer cases are diagnosed as MSI-L or MSI-H 
status. In contrast to MSS status, MSI tumors inflict a higher mutational load with 
an elevated level of tumor-specific neo-antigens (38, 39). In this study, the different 
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MSI statuses did not have significant relationships with PD-L1 expression, pre- and 
post-CRT, and the density of CD8+ TILs at pre-CRT, but MSI-H or MSI-L tumors 
had higher numbers of CD8+ TILs at post-CRT with a marginal significance. This 
lack of statistical significance might be attributable to a relatively low incidence of 
MSI-H in a study population with only rectal tumors, not proximal or mid-colon 
cancer (40), as well as incomplete MSI information for a part of the patients. 
Nevertheless, the CRT-induced immunologic shift might be helpful in expanding 
the indication and potential applicability of checkpoint inhibitors, even in MSS 
colorectal tumors. However, further mechanistic investigations are needed. 
Regarding clinicopathologic factors in relation to the density of CD8+ TILs, 
women patients showed a higher level of post-CRT CD8+ TILs. The impact of 
gender difference on tumor immunity has not been much studied yet, but this point 
of view has been discussed recently (41, 42). Wesa et al. observed higher 
frequencies of tumor-associated antigen-specific T cells in female as compared to 
male patients in melanoma (41). The gender difference might suggest the potential 
relationships between tumor immunity and hormonal or endocrine status (43, 44). 
However, in contrast to melanoma, little knowledge has been known in colorectal 
cancer. Although the gender factor was not associated with differential OS in 
multivariate analysis in this study, a large-scale population-based analysis of rectal 
cancer suggested better prognosis in women than men (45). Considering the 
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potential effects of gender on tumor-specific immune responses, further studies will 
provide useful information. 
Although the high-to-high PD-L1 group did not show a significant difference in 
LRFI, low-to-low CD8+ TIL level was associated with higher locoregional tumor 
recurrence. This conflicting result might be explained by the differential biologic 
role of CD8+ TILs and PD-L1-expressing tumor cells. The CD8+ TILs are the main 
aggressors involved in killing tumor cells, but PD-1/PD-L1 is one of the immune 
checkpoints underlying immunologic evasion of tumors (6). In regard to functional 
relationships among the immune checkpoints (46, 47), we suggest that more 
comprehensive analysis with other kinds of immune checkpoints would provide 
additional information. 
In recent years, post-treatment failures have also been addressed when treating 
patients with PD-1/PD-L1 checkpoint inhibitors (48, 49). In turn, potential 
combinatory strategies using PD-1/PD-L1-inhibiting drugs and other modalities, 
such as chemotherapy, RT, and CRT, have been proposed to enhance the long-term 
anti-tumor effects of checkpoint inhibitors (18-20). Cytotoxic treatment with CRT 
can increase the loading of tumor antigens, their related receptor molecules, and 
danger-related signal molecules, followed by cascading immune responses (50). 
Our results indicate that CRT-induced increases in CD8+ TIL density support the 
principle of an immunologic shift via interferon gamma release. In response to the 
up-regulation of anti-cancer immunity, PD-L1 expression on tumor cells may be 
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correspondingly elevated (51). The elevated number of CD8+ TILs would enhance 
the degree of anti-tumor immune responses (17, 52), whereas pre-existing CD8+ T 
cells are also required to obtain therapeutic efficacy of anti-PD-1/PD-L1 inhibitors 
(51). Therefore, this study provides initial insights into the feasibility of such 
combinatory strategies. 
It should be noted, though, that our results are incomplete. PD-L1 expression on 
infiltrating immune cells could not be assessed in the human cancer specimens, and 
we evaluated membranous staining intensity of PD-L1 on tumor cells. Kinds of 
primary tumor tissues, selection of antibody, and assay conditions can affect the 
staining patterns of each specimen. Although there have been a variety of antibodies 
for the IHC of PD-L1, some controversies have existed in regard to the standard 
staining results and antibody validation (53). Given that PD-L1 expression on tumor 
cells plays a critical role in suppressing T cell responses, and is useful for predicting 
responses to PD-L1 blockade treatment (54), this study focused on membranous 
staining results of PD-L1 on tumor cells. Time-matched comparisons between 
irradiated and non-irradiated mouse tumors might provide useful information, but 
rapidly growing tumor burden without any treatment and the potential of a 
consequent ethical problem restricted further analysis. Since the IHC of rectal 
cancer tissues was retrospectively reviewed in the era of CRT, not RT alone, 
combined chemotherapeutic effect needs to be considered together in human data. 
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Our matched analysis of PD-1/PD-L1 axis at pre- and post-irradiation status 
highlights the immunologic impact of the cytotoxic treatment on the immune 
checkpoint activity and demonstrates its prognostic associations in clinics. The RT-
induced immunologic shift resulted in a sharp increase of PD-L1 expression 
intensity on tumor cells and PD-1-positive proportions of CD8+ T cell subset. 
However, PD-L1 expression subsequently decreased within a few days from the 
time point of maximum, suggesting the need of considering concurrent combinatory 
strategy of PD-1/PD-L1 blockade and RT. A strong prognostic impact of baseline 
PD-L1 expression was observed, with the highest risk of deaths observed in the 
high-to-high PD-L1 alteration group. This comprehensive analysis of syngeneic 
mouse tumor model and patients’ data would provide useful knowledge to optimize 
the combinatory treatment of PD-L1 blockade and RT in colorectal cancer. Further 
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서론: 최근 면역 치료의 발전으로 PD-1/PD-L1 억제가 암 치료의 새로운 표
적으로 소개되었지만, 대부분 재발성이나 전이성 암에 국한하여 활용되어 
왔다. 방사선 치료는 주된 암 치료의 한 부분으로서 직접적으로 세포를 죽
이는데, 이를 통해 항종양 면역 반응이 상향 조절된다. 하지만 방사선 치료
의 PD-1/PD-L1 면역 관문에 대한 면역학적 영향에 대해서는 현재까지 많이 
논의되지 않았다. 이 연구는 마우스 대장암 종양 모델과 수술 전 항암방사
선 치료를 받은 직장암 환자 정보를 기반으로 방사선 치료에 의해 유도되
는 PD-1/PD-L1 면역 관문 분자들의 발현 변화에 대해 알아보았다. 
방법: CT26 대장암 세포주를 BALB/c 마우스 우측 뒷다리에 피하 주입했다. 
15 Gy x 1 fx 또는 5 Gy x 3 fx의 방사선 조사 후 얻어진 종양 용적 변화 곡
선 추세를 기반으로, 마우스 종양을 총 4 가지의 개별 시점에서 외과적으로 
절제했다. “방사선 치료 전 (Pre-RT)”은 방사선 치료 시작 직전 방사선 조사
가 이뤄지지 않은 상태를 의미, “초기 (Early)”은 방사선 치료 반응의 초기 
단계, “최저 (Nadir)”는 종양 용적의 최소값을 나타내는 시점, 그리고 “재성
장 (Regrowth)”은 방사선 치료 후 종양이 다시 성장하는 시기를 의미한다. 
방사선 조사 시작일을 Day 1 으로 정의했을 때, 단일 절제 선량 하에서는 
Day 1, 6, 12, 22, 분할 선량 방식 하에서는 Day 1, 6, 10, 20에 각각의 시점에 
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해당하는 개별 종양 조직을 얻었다. 종양 세포에서의 PD-L1 발현, 종양 침
윤 CD4+ 및 CD8+ T 세포군의 분율, 그리고 CD4+ 및 CD8+ T 세포에서의 
PD-1 발현 등을 유세포 분석 방식으로 측정했다. 사람 데이터와 관련하여, 
2005 년부터 2012 년에 걸쳐 수술 전 항암방사선 치료 후 수술을 시행 받은 
직장암 환자 123 명을 대상으로 항암방사선 치료 전 조직 검사 시 획득한 
검체와 이에 대응하는 항암방사선 치료 후 절제된 조직을 활용한 짝지은 
분석을 시행했다. 환자들의 임상병리학적 인자 및 생존 결과 데이터와 함
께 PD-L1, PD-1, CD8의 면역조직화학염색을 시행했다. 
결과: 마우스 종양 세포에서의 PD-L1 발현은 방사선 치료 종료 후 수일 내
에 급격히 증가했으며, 이후 “최저 (Nadir)” 및 “재성장 (Regrowth)” 시기에 
가파른 감소를 보였다 (단일 절제 선량 및 분할 선량 별로 각각 P < .001 
및 .002). 방사선 치료 효과 기간에 해당하는 “초기 (Early)” 및 “최저 
(Nadir)” 시점에서 CD4+ T 세포는 감소했지만 CD8+ T 세포는 증가했다. 
이러한 변화 경향은 “재성장 (Regrowth)” 기간에 뒤바뀌었는데, CD4+ T 세
포는 다시 증가, CD8+ T 세포는 다시 감소하는 추세를 보였다. 이러한 시
점별 차이는 통계적으로 유의했다 (모든 비교에서 P < .001). CD4+ T 세포
에서의 PD-1 양성률(%)은 시점 별로 유의한 차이가 없었다 (단일 절제 
선량 및 분할 선량 별로 각각 P = .590 및 .238). 대조적으로, CD8+ T 세포
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에서의 PD-1 양성 비율(%)은 가파르게 증가했고, 이 높은 수준은 “재성장 
(Regrowth)” 단계까지도 유지되었다 (모든 비교에서 P < .001). 
 직장암의 면역조직화학염색에서는 항암방사선 치료 후 PD-L1 발현 수준
과 CD8+ 종양 침윤 림프구 밀도가 증가한 것으로 나타났다 (두 비교에서 
P < .001). PD-1 의 경우, 항암방사선 치료 전 발현 강도는 매우 미약했으
나, 항암방사선 치료 후 눈에 띄게 증가했다. 각 발현도의 중앙값을 기준
치로 선정했을 때, 치료 전 후에 걸쳐 지속적으로 높은 PD-L1 발현(높음-
높음)을 보이는 것이 치료 후 CD8+ 종양 침윤 림프구 밀도의 보다 적은 
증가로 이어졌다 (P = .020). 치료 전 후 높은 PD-L1 발현(높음-높음)을 보
이는 환자들이 전체 생존율과 무질환 기간에서 더 나쁜 성적을 나타냈으
며 (각각 P = .018 및 .029), 치료 전 후 지속적으로 낮은 CD8+ 종양 침윤 
림프구 밀도(낮음-낮음)를 보이는 경우에 무질환 기간 성적이 더 나쁜 것
으로 관찰되었다. 다변량 분석에서 치료 전 높은 기저 PD-L1 발현을 보
이는 두 그룹이 유의하게 좋지 않은 전체 생존율을 보였는데, 치료 전 후 
지속적으로 PD-L1 이 발현이 높은(높음-높음) 그룹이 가장 높은 위험도를 
나타냈다 (치료 전 후 각각 높고 낮은 PD-L1 발현(높음-낮음)을 보이는 
그룹: 위험도 8.34, 95% 신뢰구간 [CI]; 치료 전 후 모두 높은 PD-L1 발현
(높음-높음)을 보이는 그룹: 위험도 11.03, 95% 신뢰구간 2.33–52.29). 
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결론: 본 연구는 방사선 조사에 의해 유도되는 PD-1/PD-L1 면역 관문 활성
도와 CD8+ 종양 침윤 림프구 밀도를 증가시키는 방향의 면역학적 변화를 
확인했다. 하지만 이러한 변화가 오래 지속되지는 않았고 방사선 치료 효
과가 끝난 후에 다시 회복하는 경향을 보였는데, 이는 PD-L1 억제와 방사
선 조사를 시간적으로 동시에 병합하는 치료 방침의 필요성을 강조하는 것
이라고 볼 수 있다. 이러한 면역 관문 관련 분자들의 발현 변화를 통해 나
쁜 예후를 보이는 환자 집단을 확인할 수 있었고, 항암방사선 치료와 면역 
관문 억제 병합 치료의 이득이 기대되는 잠정적인 후보 환자군을 제시했다. 
 
* 본 내용의 일부는 미국방사선종양학회지 (International Journal of Radiation 
Oncology ▪ Biology ▪ Physics. 2017;99(5):1216-24)에 출판되었음. 
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